ArticleOncology and therapy2026

Time and Resource Implications of Subcutaneous Daratumumab-Based versus Intravenous Isatuximab-Based Treatment Regimens for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible.

Emma Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.